New Insights into Esketamine Treatment: Efficacy, Safety, and Long-Term Effects
March 4, 2025
Intranasal esketamine has been approved as an adjunctive pharmacoth...
Read More
Deprescribing Antidepressants in Children and Adolescents
March 3, 2025
When considering the discontinuation of antidepressant treatment, f...
Read More
Associations Between Biomarkers of Inflammation and Depressive Symptoms
February 7, 2025
A recent study published in Translational Psychiatry has provided ...
Read More
Depressive Symptoms and Amyloid Pathology
February 1, 2025
A recent large-scale study examined the association between depress...
Read More
Effectiveness of Antidepressant Treatments In TRD
January 10, 2025
A comprehensive network meta-analysis recently published offers new...
Read More
The Role of Inflammation in Mental Health
November 9, 2024
Inflammation triggers chemical reactions in the body that can direc...
Read More
Medication-Induced Weight Change Across Common Antidepressant Treatments
October 9, 2024
While antidepressants rank among the most frequently prescribed dru...
Read More
Inflammatory Biomarkers and Risk of Psychiatric Disorders
October 5, 2024
A recent study investigates whether certain inflammatory markers i...
Read More
Poor Sleep Associated with Poorer Antidepressant Response
September 23, 2024
Poor sleep is common in treatment-resistant late-life depression an...
Read More
Esketamine versus Quetiapine Extended Release in Adults with TRD
August 5, 2024
A recent study compared the adverse effects and overall safety of e...
Read More
TMS Treatment Device Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
April 23, 2024
The FDA has recently granted clearance of a transcranial magnetic s...
Read More
Positive Phase 3 Topline Results Evaluating Lumateperone as Adjunctive Therapy for MDD
April 22, 2024
Encouraging results from a Phase 3 clinical trial evaluating lumate...
Read More